PYCARD and Parkinson disease: Exogenous administration of several miRNAs (miR-30e, miR-190, miR-7) to Parkinson’s disease mice models inhibits NLRP3, ASC, and caspase-1 expression, impairing the release of IL-1β and IL-18, limiting pyroptosis and, consequently, neuroinflammation and neuronal damage [91,92,93].